Chemicon and Australian Stem Cell Center to Commercialize Stem Cell Reagents | GenomeWeb

NEW YORK, April 21 (GenomeWeb News) - Serologicals said today that its Chemicon International subsidiary has signed an agreement with the AustralianStemCellCenter that will allow Chemicon exclusive rights to commercialize, market, and distribute stem cell reagents developed by ASCC worldwide.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.